CRYbetaB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer. Yan Y, Narayan A, Mazinani M, Saeki H, et al. Breast Cancer Res 2026 Jan 14. doi: 10.1186/s13058-025-02188.

Read + Share

Amedeo Smart

Independent Medical Education

Yan Y, Narayan A, Mazinani M, Saeki H, et al. CRYbetaB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer. Breast Cancer Res 2026 Jan 14. doi: 10.1186/s13058-025-02188.
PMID: 41535871